Synopsis

Source of validity: Scientific
Rating (out of 5): 2

β-Nicotinamide mononucleotide (NMN) is a precursor to nicotinamide adenine dinucleotide (NAD+), a vital coenzyme involved in cellular energy metabolism and mitochondrial function. In the context of congestive heart failure (CHF), there is a growing body of preclinical evidence suggesting that NAD+ depletion contributes to cardiac dysfunction and that boosting NAD+ levels may improve cardiac energetics and function. Several animal studies have demonstrated that NMN supplementation can enhance NAD+ biosynthesis, improve mitochondrial efficiency, reduce oxidative stress, and attenuate cardiac remodeling in models of heart failure. For example, a 2019 study published in Science found that NAD+ repletion via NMN administration improved cardiac function and survival in mouse models of heart failure.

However, while these preclinical findings are promising, direct clinical evidence in humans with CHF is currently limited. To date, most human NMN research has focused on metabolic health, aging, and exercise performance rather than specifically on CHF. No large-scale, randomized controlled trials have yet established the efficacy or safety of NMN supplementation in patients with congestive heart failure. Thus, while there is a strong scientific rationale and supportive animal data, clinical validation in humans is lacking, and the evidence level is moderate at best (rated 2/5). More research, particularly human clinical trials, is needed to determine NMN’s therapeutic potential in CHF.

More about β-nicotinamide mononucleotide (NMN)
More about Congestive Heart Failure

Other ingredients used for Congestive Heart Failure

Other health conditions supported by β-nicotinamide mononucleotide (NMN)

Products containing β-nicotinamide mononucleotide (NMN)

Designs For Health Liposomal NMN Synergy 1.7 fl oz (50 ml) liquid. Nonreturnable item.